Arena: Market Conditions Before Inovalon
Quality and Medicare teams at US health plans and HMOs · 1998 · United States
Regulatory constraintsDisconnected workflows
By 1998 US health plans were graded on HEDIS, a set of quality measures the National Committee for Quality Assurance had maintained since 1991 and revised as version 3.0 in 1997; it was part of NCQA accreditation, and Medicare required its HMOs to report the measures INV22. Producing the numbers meant joining claims, pharmacy, laboratory and enrollment records, and many measures were only credible with the hybrid method, in which nurses abstracted paper medical records, a costlier and slower route than counting claims INV22. Treatment data sat in separate systems, and little computing was applied to it outside imaging equipment INV1 INV15. Plans settled for administrative counts where they could and sent reviewers into physician offices where they could not INV22.
What shaped the outcome
Step 1 of 4 · 1998–2012 · Health plan quality and risk analytics
A doctor-programmer's company bought the leading HEDIS engine and became where health plans computed their quality scores
Keith Dunleavy paid his way through Dartmouth by programming and started the business in 1998 from a spare room while a medical resident at Johns Hopkins INV16 INV25. He later said he had been amazed at how little computing was applied to treatment data INV1, and that the company began just as quality became a regulated part of health plans' work, analyzing the information plans needed to meet quality and accreditation standards INV2. NCQA certified HEDIS software by running each vendor's engine on test data; a plan using certified software skipped the manual source code review in its HEDIS audit, which a plan computing measures with its own code still faced INV41 INV42. Catalyst Technologies, founded in 1996 near Atlanta, was on NCQA's December 2001 certified list, where the company was not INV42 INV18. The company launched its own quality measurement product in 2003 INV15, and in 2008 NCQA certified it as one of eight HEDIS software vendors, alongside Catalyst, McKesson and DST INV41. In 2009 it bought Catalyst, the leading HEDIS reporting vendor, for cash and stock with no debt, gaining its HEDIS software and analytical rules compiler and reaching over 200 managed care organizations, including half of the top 20 INV18 INV55. It retired the Catalyst name in 2011 and sold the engine as Quality Spectrum Insight (QSI) within its Quality Spectrum Insights suite INV61. By 2012 QSI had passed NCQA certification 11 years in a row, a streak dating from 2001, and was described as the most widely used HEDIS solution, supporting quality calculations for about 60% of insured Americans INV33. Verisk Health's Quality Intelligence engine, also certified every year since 2001, processed claims for about 21% of the insured population in 2013 INV63. Clarian Health Plans, for example, bought HEDIS analytics in 2008 before adding more INV21. In 2026 the successor product, Converged Quality, earned its 26th consecutive certification and processed measures for over 85% of HEDIS covered lives, including 12 of the 15 largest plans INV56.
HEDIS was an annual, rule-defined job every accredited and Medicare plan had to complete, and certification made buying an engine cheaper than auditing one's own code. Certification itself was common, so among vendors the contest was installed base: the company entered with its own product and services, then bought the leader whose certification record and plan list predated it. That purchase turned one of eight certified vendors into the default, three times the reach of Verisk Health's engine, and owning the calculation put the company inside each client's claims, pharmacy, lab and chart data, which every later product reused.
Rivals Plans could compute measures in-house and send nurses to abstract charts INV22; the company's prospectus called persuading plans to use its platforms "rather than developing or assembling their own alternative capabilities" its primary competitive challenge INV61. Among vendors, NCQA certified ten engines in December 2001 and eight in 2008, including McKesson, DST and ViPS INV42 INV41. Verisk Health, which entered plan analytics by acquisition in 2004, kept its Quality Intelligence engine certified from 2001 INV36 INV63; renamed Verscend, it served more than 100 organizations and won KLAS's 2017 award for payer quality analytics INV64. Plan quality directors still called the company's software "the biggest game in town" and "the 800-pound gorilla" in 2025 and 2026, while one plan weighed consolidating onto another vendor INV48.
Regulatory constraintsM&A Strategy
Step 2 of 4 · 2004–14 · Health plan quality and risk analytics
Medicare Advantage turned the same plan data into revenue work, and the company sold plans both software and its own clinicians
Dunleavy credits the 2003 Medicare Modernization Act: plans entering Medicare Advantage needed the company's analytics and data aggregation to succeed INV2. Medicare paid those plans more for sicker members, based on documented diagnoses, and graded them on Star ratings INV35 INV19. By 2008 the company had about 1,800 to 1,900 employees, described as clinicians and statisticians, and sold patient assessment (ePASS), patient stratification and on-site medical record review (SRSA) alongside analytics INV17 INV24. Clarian expanded in 2010 from HEDIS to risk-score accuracy, quality and utilization INV21; Healthfirst widened its use across Medicare and Medicaid in 2011 INV20; and Blue Cross Blue Shield of Michigan put eight products on one data feed for Medicare Advantage, including Star quality management, capitated risk adjustment and claims submission INV19. One Medicare Advantage client that started in 2009 grew from about 80,000 to nearly 150,000 members and from 3 to 4 Stars while using QSI, ePASS and five other toolsets, by the company's account INV61. In 2013 such services were 51.4% of revenue INV3.
The quality engine already held each plan's data, so finding undocumented diagnoses and Star gaps was a second use of the same feed, and the company's own nurses and clinicians then closed those gaps in charts and homes. Selling the analytics and the field work together let one vendor deliver a measurable payment and rating gain, which a plan buying separate tools and staffing would have had to assemble itself. That revenue depended on Medicare's payment rules, and MedPAC later found chart reviews and home assessments drove about half of Medicare Advantage coding intensity INV35.
Rivals Plans' own coding and nurse teams, separate chart-retrieval vendors and analytics firms INV4. The prospectus named McKesson, OptumHealth, Truven and Verisk as large healthcare rivals and DST Health, The Advisory Board, Altegra and others as point solutions INV61; Verisk Health had added medical record retrieval software by buying MediConnect in 2012 INV36. By 2017 the company named Optum, Change Healthcare, Verscend and IQVIA as large healthcare rivals INV44. In KLAS's 2018 survey of 84 plans, only 59% of the company's customers counted it in their long-term plans, down from 70% a year earlier, citing slow innovation and post-implementation support, while Change Healthcare led satisfaction and Verscend drew clients on product quality and usability INV46. In 2020 KLAS named Change Healthcare, Cotiviti, Inovalon and Optum as the four dominant risk adjustment analytics vendors; non-customers called Inovalon capable but expensive and said it oversold INV47.
Land and ExpandMulti-ProductTech-Enabled Services
Step 3 of 4 · 2000–26 · Health plan quality and risk analytics
Every client's data went into one de-identified registry that later became a product of its own
Data received in serving clients was kept in client-specific stores and also statistically de-identified into the MORE2 Registry INV3 INV4. The prospectus said the registry had grown about 43.3% a year since 2000, reaching 9.1 billion medical events on 118 million patients by September 2014 INV7; it held 4.5 billion events in 2011 INV19 and 63 billion by 2021 INV30. The company listed it among its main strengths as one of the largest independent datasets INV7. From 2014 registry studies appeared at outcomes-research meetings INV27; by 2016 the company served 219 life sciences organizations INV4, and pharma and life sciences clients supplied 14% of revenue in 2015 and 15% in 2016 and 2017, a share that includes Avalere's advisory work INV45 INV44 and by 2021 all of the top 25 drug companies INV30. In 2026 it sells de-identified real-world data from over 160 sources and linked its closed claims with OMNY Health's EHR records for researchers INV28 INV32.
The registry was a by-product of the plan work: each new plan's annual feeds added longitudinal history the company could reuse in analytics and sell to a different buyer, drug companies. A newcomer could match the software but would need years of contracts with many plans to rebuild comparable history. The strongest counterweight is that large insurers own their members' data outright, and UnitedHealth's Optum has its own.
Rivals Optum, inside UnitedHealth, holds its parent's claims INV37; Verisk Health ran more than 2.2 billion claims a year through its quality engine in 2013 INV63; data vendors and plans' own warehouses are the other sources INV4.
Data Exhaust
Step 4 of 4 · 2013–21 · Provider connectivity and life sciences data
Reliance on a few plans turned two 2016 setbacks into a crash, and a debt-funded purchase of provider reach rebuilt growth
The company grew without private-equity money; Roche vice chairman Andre Hoffmann, a backer since 2004, bought $175 million of stock in 2008 INV17 INV53, and Dunleavy kept about 64% INV16 and voting control through ten-vote shares INV3. It listed in February 2015, raising about $600 million at $27 INV8. Its revenue came through multiple statements of work with a few plans: the top four were 44% of 2013 revenue and the top ten about 75%, and 2013 revenue fell about 1% partly because one client dropped several integrated engagements INV7 INV61; Anthem alone was 17% in 2016 INV4. In August 2016 it cut revenue guidance from $510 to $520 million to $470 to $490 million, citing a slower sales ramp and clients leaving an older product line faster than planned while it converted them to a more modular platform INV50. That December a counterparty withdrew from a multiyear collaboration worth about $40 million in the quarter, citing a development of its own unrelated to Inovalon's products; guidance fell to $426 to $428 million and the shares fell 35%, about 70% below their 2015 peak INV49 INV5 INV6 INV29. Its top ten clients were still 53% of 2017 revenue, and payers fell from 83% of revenue in 2015 to 69% in 2017 as provider and pharma work grew INV44 INV45. In 2018 Inovalon paid $1.2 billion for ABILITY Network, whose software connected more than 44,000 provider facilities to Medicare and insurers and brought about $140 million of 2017 revenue, funded largely with a $980 million loan INV13 INV14. Dunleavy described the deal as "dramatically expanded reach" from the health plan down to where patients get care INV51, and it was reported as lessening reliance on insurers INV14. Revenue rose from $449 million in 2017 to $528 million in 2018 INV40 and $667.5 million in 2020, by then 86% subscription in the fourth quarter INV39. A Nordic Capital-led group took it private at $41 a share in November 2021, a $6.4 billion equity value INV9 INV11.
Two separate hits landed in 2016: clients left an older product faster than planned, and one large deal collapsed for reasons outside the company. Both hurt because a few plans and large one-off contracts made up so much of revenue, and the public market punished the lumpiness. ABILITY bought a recurring provider base and a channel to tens of thousands of facilities the company did not reach, shifting the mix toward subscriptions before the sale. Earlier deals widened the menu (Avalere was later sold INV38), but ABILITY was the one large enough to change the revenue mix.
Rivals Optum, which added Change Healthcare's provider connectivity in 2021 and 2022 INV37. Verisk Health took a different route to scale: Veritas Capital bought it in 2016, and as Verscend it bought Cotiviti, a payment accuracy firm that competed with Optum, Verisk Health, McKesson, Change Healthcare and HMS, for $4.9 billion in 2018 and took the Cotiviti name INV36 INV62 INV65. When William Blair valued Cotiviti for that sale, it grouped Inovalon with Cerner, athenahealth, HMS and IQVIA as healthcare technology peers, at 4.6 times trailing revenue INV54.
M&A Strategy